Matteo Riva

TL;DR: The therapeutic activity of NDV against GL261 tumors, evidenced in an orthotopic mouse model, is described for the first time, and the importance of a functional adaptive immune system in this paradigm was demonstrated in immunodeficient Rag2−/− mice and in CD8+ T cell depleted animals, where NDV slightly prolonged survival, but failed to induce long‐term cure.

TL;DR: This work discusses the effects of three immunogenic treatment modalities and five potent inducers of immunogenic cell death on DC biology and their application in DC-based immunotherapy in preclinical as well as clinical settings.

TL;DR: It is concluded that the adaptive immune system does not efficiently control tumor growth in the ID8-fLuc syngeneic ovarian cancer mouse model and a prominent role for MDSC as the driver of immunosuppression is discovered.

TL;DR: Because a proportion of mis‐clippings cannot be identified with ICG‐VA, this technique should still be considered complementary rather than a replacement to DSA during aneurysm surgery.

TL;DR: Because of the failure of immunotherapy as single agent in a number of cancers, current clinical trials are focusing on combining immunotherapy with other therapies, with almost no preclinical data on this combination available.